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Investigations into brain function and disease depend on the precise classification of neural cell types. Cells of
the oligodendrocyte lineage differ greatly in their morphology, but accurate identification has thus far only
been possible for oligodendrocyte progenitor cells and mature oligodendrocytes in humans. We find that
breast carcinoma amplified sequence 1 (BCAS1) expression identifies an oligodendroglial subpopulation in
the mouse and human brain. These cells are newly formed, myelinating oligodendrocytes that segregate from
oligodendrocyte progenitor cells and mature oligodendrocytes and mark regions of active myelin formation in
development and in the adult. We find that BCAS1+ oligodendrocytes are restricted to the fetal and early post-
natal human white matter but remain in the cortical gray matter until old age. BCAS1+ oligodendrocytes are
reformed after experimental demyelination and found in a proportion of chronic white matter lesions of pa-
tients with multiple sclerosis (MS) even in a subset of patients with advanced disease. Our work identifies a
means to map ongoing myelin formation in health and disease and presents a potential cellular target for re-
myelination therapies in MS.cie




Oligodendrocytes wrap several layers of their plasma membrane
around axons to generate myelin (1), which provides electrical insula-
tion to increase the speed of nerve conduction (2). Oligodendrocyte and
myelin development progresses along a typical chronological and topo-
graphic sequence, starting in areas related to basic homeostasis and pro-
gressing to regions controllingmore complex functions (3).However, in
mice, myelin formation is not only a developmental process driven by a
predefined intrinsic programbut also extends into adulthoodwhere it is
regulated by environmental factors (4–6). The developing and adult
mouse central nervous system (CNS) both contain an abundant popu-
lation of oligodendrocyte progenitor cells that continuously generate
oligodendrocytes (7) and provide a source for reforming myelin after
injury (8). Both oligodendrocyte progenitor cell proliferation and differ-
entiation can increase within active neuronal circuits, and there is evi-
dence that adult-born oligodendrocytes are actively engaged in formingnewmyelin sheaths inmice (9–11). For example, in adultmice, learning
a new motor task is associated with changes in white matter structure
(12). In humans, a large number of studies have demonstrated white
matter changes upon learning and training, such as extensive piano
playing (13), suggesting de novo myelination upon neuronal stimula-
tion (14). However, human studies are often based on magnetic reso-
nance imaging, which does not provide direct information on myelin;
therefore, whether and how brain activity modulates myelin changes is
not well understood. Birth dating of oligodendrocytes, by analysis of the
integration of nuclear bomb test–derived 14C into cells, provided evi-
dence for the generation of only few new oligodendrocytes in the adult
human corpus callosum (15), suggesting that adaptive myelination in
the white matter of humans may be more limited as compared to mice.
Evidence for the de novo formation of myelin in adults comes from
studies on human demyelinating diseases, of which multiple sclerosis
(MS) is the most prevalent. On average, in MS, only 20% of patients
display efficient (above 60%) remyelination of lesions as shown by histo-
chemistry in areas of pale myelin stain called “shadow plaques” (16).
Currently, no molecular marker exists that allows the discrimination
ofmyelinated from remyelinated axons, and ongoingmyelination is no-
toriously difficult to detect; consequently, it has thus far not beenpossible
to determine whether newmyelin sheaths are formed in chronically de-
myelinated MS lesions. Because failure of remyelination contributes to
disease progression inMS, remyelinating oligodendrocytes might repre-
sent an important drug target. Here, we set out to develop a newmethod
to visualize actively myelinating oligodendrocytes in mouse and human
to map areas of active myelination in health and disease. This led to the
identification of breast carcinoma amplified sequence 1 (BCAS1) as a
marker for ongoing myelination and remyelination. BCAS1 was origi-
nally identified as mRNA amplified in human cancer cell lines (17), but
recent transcriptome studies have shown that it is also highly expressed
in the brain and, more specifically, in oligodendrocytes (18). The1 of 12
SC I ENCE TRANS LAT IONAL MED I C I N E | R E S EARCH ART I C L Efunction of BCAS1 is unknown, but there is evidence that it interacts
with the dynein light chain (19) and is required for brain function be-
cause its absence results in reduced anxiety and schizophrenia-like be-
havioral abnormalities in mice (20).
We found that BCAS1+ cells represent a population of oligodendro-
cytes that segregates from mature oligodendrocytes and their progeni-
tors in humans. Our results show that in humans, the high density of
BCAS1+ oligodendrocytes is only found in the white matter in the fetal
and early postnatal period, whereas in the frontal cortex, oligodendro-
cytes expressing BCAS1 are numerous throughout adulthood. We ob-
served BCAS1+ oligodendrocytes at the lesion edge in a proportion of
fully demyelinated white matter lesions in MS patients, suggesting that









BCAS1 expression identifies newly
generated oligodendrocytes
We examined our previously generated proteome database for oligo-
dendrocyte specific proteins and noticed that BCAS1 was one of the
most enriched proteins in oligodendrocytes (21). We generated a poly-
clonal antibody (see Supplementary Materials for details) against
BCAS1 and validated its specificity by preabsorption of the antibody
with recombinant BCAS1 protein before immunolabeling. Preabsorp-
tion eliminated staining of mouse brain sections (fig. S1A). In addition,
transfections ofBcas1 cDNA(complementaryDNA) into neuroblastoma
cells followed by immunofluorescence staining showed labeling only in
transfected cells (fig. S1B), and costaining of the polyclonal antiserum
with anti-BCAS1mousemonoclonal antibody on themouse and human
brain section revealed overlapping staining pattern (fig. S1C). Finally,
abolished BCAS1 immunoreactivity on adult Bcas1 knockout mouse
brain sections demonstrated that the staining was specific for BCAS1
(fig. S1D).
Immunofluorescence on frozen mouse tissue sections of the corpus
callosum and somatosensory cortex [postnatal day 40 (P40) and
4 months] showed that all BCAS1+ cells were of the oligodendrocyte
lineage, as shownby colabelingwith the lineagemarkers, sex-determining
region Y box 10 protein (SOX10), oligodendrocyte transcription factor
1 (OLIG1), and OLIG2 (Fig. 1, A and B, and fig. S2, A and B). Immuno-
labeling with antibodies against neural/glial antigen 2 (NG2; amarker for
oligodendrocyte progenitor cells) revealed that a small fraction (16.5 ±
2.8%) of the BCAS1+ cells were oligodendrocyte progenitor cells (Fig. 1C).
The remaining cells weremore differentiated, as shownby their reactivity
with antibodies against mature oligodendrocytes such as adenomatous
polyposis coli protein (76.2±3.5%of overlap) (Fig. 1C; anti-adenomatous
polyposis coli antibody, clone CC1) and myelin-associated glycoprotein
(MAG; 47.5±3.2%of overlap), a protein involved inoligodendrocyte and
axon contact (Fig. 1C).
To analyze whether BCAS1+ cells were newly formed oligodendro-
cytes, we performed fate mapping experiments. We crossbred trans-
genic mice expressing a tamoxifen-inducible Cre DNA recombinase
inserted into the NG2 locus [NG2-CreERT2 (22)] with a widely used
reportermouse strain containing amembrane-targeted enhanced green
fluorescent protein (EGFP) gene inserted into the Gt(ROSA)26Sor locus
(23). NG2-CreERT2×R26R-tdTomato-membrane EGFP (mEGFP)mice
were injected with tamoxifen at P30 to induce Cre-dependent GFP
expression in oligodendrocyte progenitor cells. When we analyzed the
progenies of the labeled cells at 7, 18, and 40 days after injection by
immunostaining, we observed an increase in the number of cells co-Fard et al., Sci. Transl. Med. 9, eaam7816 (2017) 6 December 2017expressing BCAS1 and GFP from days 7 to 18 in the somatosensory
cortex, indicating that BCAS1+ cells differentiate from oligodendrocyte
progenitor cells (Fig. 1D).
BCAS1+ premyelinating and myelinating oligodendrocytes
are present during development and in adult mice
Immunofluorescence on somatosensory cortex during postnatal devel-
opment (P40) showed that BCAS1was expressed inCC1+ oligodendro-
cytes with different morphologies—cells with multiple, symmetrically
radiating processes and with several segments aligned in parallel
(fig. S3A). Oligodendrocytes that radially extend processes are reminis-
cent of previously described premyelinating oligodendrocytes at an early
stage of the oligodendrocyte differentiation (24, 25). To determine
whether BCAS1+ cells with radiating processes represent premyelinating
oligodendrocytes, we used transgenicmice, inwhich the proteolipid pro-
tein (PLP) promoter drives the expression of GFP (PLP-GFP) (26). PLP
is one of the major structural proteins in myelin and therefore not only
highly expressed in mature myelin-forming oligodendrocytes but also
present in premyelinating cells during development (24). We detected
GFP+ premyelinating oligodendrocytes in early postnatal development
(P9 andP14), whenmanyoligodendrocytes are formed (Fig. 2, A andB).
Whereas all of the GFP+ premyelinating oligodendrocytes also showed
immunoreactivity against BCAS1, most of the BCAS1+ premyelinating
cells (70.5 ± 8.1% at P9 and 76.3 ± 1.7% at P14) did not express GFP,
demonstrating that BCAS1 is expressed in a larger population of newlyFig. 1. BCAS1 expression identifies newly generated oligodendrocytes. (A) Con-
focal images of breast carcinoma amplified sequence 1 (BCAS1) (pink) and oligo-
dendrocyte transcription factor 2 (OLIG2) (white) in the corpus callosum (CC) of
postnatal day 40 (P40) mice. Scale bars, 5 mm. (B) Bar graph shows the percentage
of BCAS1+ cells expressing sex-determining region Y box 10 protein (SOX10),
OLIG1, or OLIG2. (C) Bar graph shows the percentage of BCAS1+ cells expressing
neural/glial antigen 2 (NG2), CC1, or myelin-associated glycoprotein (MAG) in the
corpus callosum of P40 mice. (D) Left (experimental plan): NG2-CreERT2 × R26R-
tdTomato-mEGFP mice were used to induce the expression of mEGFP by tamoxifen
(TMX) at P30 as illustrated. Right: Quantification of the percentage of double-positive
[GFP+ (green fluorescent protein–positive) and BCAS1+] cells over time. One-way
analysis of variance (ANOVA), followed by Bonferroni’s post hoc test, *P < 0.05; n = 3,
three sections per animal. Quantitative data are means ± SEM.2 of 12
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 formed oligodendrocytes in the somatosensory cortex at both P9 and
P14 (Fig. 2B). When the analysis was performed in the adult somato-
sensory cortex (at 4 months), we found that all BCAS1+ premyelinating
oligodendrocytes were negative for GFP, suggesting that the previ-
ously identifiedPLP+ premyelinating oligodendrocytes constitute a sub-
population (29.5 ± 8.1% at P9, 23.7 ± 1.7% at P14, and 0% at 4months)
of oligodendrocytes present only during development (Fig. 2B). Thus,
a PLP−/BCAS1+ premyelinating subpopulation may be involved in
continued oligodendrogenesis in the adult.Fard et al., Sci. Transl. Med. 9, eaam7816 (2017) 6 December 2017Next, we analyzed the other major population of BCAS1+ oligoden-
drocytes, the cells with T-shaped processes that resemble myelinating
oligodendrocytes by morphology. Because many of these BCAS1+ cells
contained numerous processes aligned in parallel reminiscent ofmyelin
sheaths, we tested whether these cells were producing myelin segments
enwrapping axons. High-resolution confocal images of somatosensory
cortex sections confirmed ensheathment of axons by BCAS1+ segments
as shownby costainingwith antibodies against a neurofilament (Fig. 2C).
A total of 17.1 ± 1.9% of these BCAS1+ cells displayed myelin segmentsFig. 2. BCAS1+ premyelinating and myelinating oligodendrocytes are present during development and in adult mice. (A) Immunohistochemical analysis of
transgenic mice in which the proteolipid protein (PLP) promoter drives the expression of GFP (PLP-GFP mice); representative confocal images show BCAS1 (pink) and
GFP (green) expression in premyelinating oligodendrocytes (pre-mOLGs) in the developing and adult somatosensory cortex (CX) of P9, P14, and 4-month-old mice. Blue
arrows indicate BCAS1+/GFP−, and yellow arrows indicate BCAS1+/GFP+ pre-mOLGs. Scale bars, 10 mm. (B) Quantification of the percentage of pre-mOLGs positive for
GFP, BCAS1, or both in the somatosensory cortex of P9, P14, and 4-month-old mice. Student’s two-tailed t test, unpaired,*P < 0.05, ***P < 0.001. (C) Representative
confocal image of BCAS1+ segments (pink) aligned along neurofilament-positive (white) axons in the somatosensory cortex of P15mice. Scale bar, 4 mm. (D) Left: Representative
confocal image of BCAS1+ segments (pink) flanked by contactin-associated protein 1 (CASPR) clusters (white) on both sides of a node in the somatosensory cortex of P15 mice.
Scale bar, 3 mm. Right: Quantification of the percentage of nodes in the somatosensory cortex of P15 mice showing BCAS1+ segments and CASPR expression on one side (one
BCAS1+ paranode), both sides (two BCAS1+ paranodes), or without BCAS1+ segments (zero BCAS1+ paranode). (E) Representative confocal images showing BCAS1 (pink) andGFP
(green; PLP-GFP mice) expression in myelinating (mOLGs) in the developing and adult somatosensory cortex of P9, P14, and 4-month-old mice. Blue, yellow, and white arrows
showBCAS1+/GFP−, BCAS1+/GFP+, and BCAS1−/GFP+mOLGs, respectively. Scale bars, 10 mm. (F) Quantification of the percentage ofmOLG positive for GFP, BCAS1, or both in the
somatosensory cortex of P9, P14, and 4-month-oldmice. Quantitative data aremeans ± SEM; n=3, three sections per animal [onlyn=2 for P9 in (F)]; one-wayANOVA, followedby
Bonferroni’s post hoc test, ***P < 0.001. (G) Schematic illustration of the phases of OLG maturation and the relative expression of NG2, CC1, and BCAS1. OPCs, oligodendrocyte
progenitor cells. (H) Schematic illustration representing the pattern of the expression of BCAS1 and PLP (green) during development and in adulthood.3 of 12
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 with a patchy arrangement along the axons resembling the previously
reported “intermittent myelin” of cortical pyramidal neurons (fig. S3B)
(27). Because the formation of myelin is accompanied by the generation
of axon-glial junctions, so-called paranodes, at the edges of the sheaths
(28), we immunostained the somatosensory cortex of P15 mice for the
neuronal and paranodal protein contactin-associated protein 1. BCAS1+
segments were flanked by contactin-associated protein 1 clusters on
one side (one paranode, 17.1 ± 1.9%) or both sides (two paranodes,
62.2 ± 2.9%), indicating the formation of myelin sheaths (Fig. 2D).
The ensheathment of axons together with the formation of axon-glial
paranodal junctions define the BCAS1+ cells with segments aligned in
parallel as myelin-forming oligodendrocytes.
To further analyze these cells, we used the PLP-GFP reportermice to
visualize myelinating oligodendrocytes and found that, at P9, all GFP+
myelinating oligodendrocytes were also positive for BCAS1 (Fig. 2, E
and F). However, when the analysis was performed at P14, a population
of GFP+ myelinating oligodendrocytes that lacked BCAS1 expression
emerged (Fig. 2, E and F), suggesting that BCAS1 expression is lost
when oligodendrocytes mature into later stages of oligodendrocyte
differentiation (Fig. 2, G andH). At 4months, we observed a complete
segregationofGFP+ andBCAS1+myelinating oligodendrocytes (Fig. 2F).
To verify the segregation of BCAS1+ and PLP+ oligodendrocytes in
adultmice, we crossbred transgenicmice expressing a tamoxifen-inducible
Cre inserted into the PLP locus (PLP-CreERT2) with GFP reporter mice
(R26R-tdTomato-mEGFP).We injected tamoxifen at P110 to induceGFP
expression in oligodendrocytes (fig. S3C). When brain sections were
analyzed by immunohistochemistry 18 days after injection, no overlap
between BCAS1+ and GFP+ cell populations was seen in adult mice
(fig. S3C). In addition, immunostainings of the somatosensory cortex of
adult wild-type mice showed that BCAS1+ myelinating oligodendro-
cytes were only positive for MAG and negative for PLP and that only
few (17.7 ± 4.3%) expressed myelin basic protein (MBP), supporting
our hypothesis that these cells constitute a distinct population of oligo-
dendrocytes (fig. S3,D toG). Thus, BCAS1+ cells represent a population
of oligodendrocytes that are at an intermediate state of differentia-
tion, segregating from both oligodendrocyte progenitor cells andmature
oligodendrocytes.
Ectonucleotide pyrophosphatase/phosphodiesterase 6 (ENPP6) has
recently been used as a marker to track the formation of newly formed
oligodendrocytes (9). When we analyzed the corpus callosum and the
fimbria hippocampi, a further prominent whitematter tract, we found a
significant increase in ENPP6+ cell bodies from P0 to P7 in the fimbria
(P = 0.0291) and a significant decrease until P21 (P = 0.0405). In addi-
tion, BCAS1+ cells were abundant in the fimbria at P7 and decreased
until P21 (fig. S4, A to C). However, higher densities of BCAS1+ cells
were identified already at P0 (in the fimbria), and BCAS1+ cells con-
tinued to bemore abundant as compared to ENPP6+ cells in the corpus
callosum and fimbria at P7 and in the corpus callosum at P21. At P7,
BCAS1+ cells coexpressingMAGwere found to bemore abundant than
ENPP6+/MAG+ cells, indicating that myelin protein expression starts
earlier in BCAS1+ cells (fig. S4, D and E).
BCAS1+ cells represent a transient population
of oligodendrocytes
To determine the expression of BCAS1 during oligodendrocyte differ-
entiation, we used primary cultures of oligodendrocytes. After ~3 days
in culture, oligodendrocytes progenitor cells start to differentiate into
oligodendrocyteswithmultiple, symmetrically radiatingprocesses,which
further mature into with flat myelin-like membrane sheets, in whichFard et al., Sci. Transl. Med. 9, eaam7816 (2017) 6 December 2017proteins and lipids ofmyelin, such asMBP, PLP, and galactosylceramide/
sulfatide (recognized by the antibody O4), are localized. BCAS1 was
expressed in 85.9 ± 2.2% of the population of O4+ oligodendrocytes with
arborizedmorphology at 3 days in vitro (fig. S5A). However, after 5 days
in culture, when oligodendrocytes formed sheets and expressedMBP, we
observed a reduction in BCAS1 immunolabeling (fig. S5B). BCAS1 was
virtually excluded from the compactedmyelin-likemembrane sheets but
remained at low levels in the cytosol-enriched, noncompacted areas
(fig. S5C). This is in contrast to galactosylceramides/sulfatides (recog-
nized byO1 andO4 immunolabeling), another oligodendroglialmarker,
which remain enriched in myelin sheets of differentiated cells in vitro
(fig. S6A) and in vivo (fig. S6B). To extend the analysis to human cells,
we generated oligodendrocytes from induced pluripotent human stem
cells (iPSCs) derived from healthy human adults (29). We found that
BCAS1 was expressed in 86.1 ± 2.3% of the O4+ oligodendrocytes with
arborized morphology at 24 days in vitro (fig. S7A). To analyze the cells
at a later time point of differentiation, we performed immunolabeling
against MBP at 32 days in vitro, when cells have formed myelin-like
membrane sheets. We found that only 4 ± 1.2% of the fully mature
MBP+ oligodendrocytes were labeled with antibodies against BCAS1
(fig. S7B), demonstrating the enrichment of BCAS1 at an early differ-
entiation stage in both mouse- and human-cultured oligodendrocytes.
To determine whether BCAS1 is also transiently expressed in oligo-
dendrocytes in vivo, we used 5-ethynyl-2′-deoxyuridine (EdU), a thy-
midine analog, to pulse-label dividing cells followed by a chase to
identify the progeny of dividing cells (Fig. 3, A to D). When EdU was
administered for 10 days via the drinking water to 4-month-old mice,
65 ± 2.7% of the BCAS1+ cells incorporated EdU (Fig. 3B). Notably,
after 40 days of a “chase” only, 7.7 ± 1.3% of the EdU+/BCAS1+ cells
were left revealing their transient nature (Fig. 3B). To exclude dilution
of the EdU labeling as the underlying reason, we also visualized mature
oligodendrocytes by immunolabeling for CC1 in the corpus callosum.
As expected, we found an increase in the number of EdU+/CC1+ in
BCAS1− cells at day 18 (but not significant at day 40), indicating their
differentiation into a stable population of oligodendrocytes (Fig. 3D).
Thenumber ofEdU+/CC1+/BCAS1+ cells, however, decreasedwith time,
confirming our conclusion of their transient nature (Fig. 3D). When
similar experiments were performed in the somatosensory cortex, we
observed that only 12.1 ± 1.5% of the BCAS1+ cells incorporated EdU
after 10 days of administration (+0 days; Fig. 3C). In contrast to the
corpus callosum, the fraction of EdU+/BCAS1+ cells increased slightly
to 17.9 ± 1.1% after 40 days of a chase (+40 days; Fig. 3C). In addition,
analysis of premyelinating and myelinating oligodendrocytes individu-
ally showed that the number EdU+/BCAS1+ remained stable after the
chase (fig. S8, A and B). Thus, BCAS1+ cells constitute a transient cell
population in the corpus callosum but not in the cortex.
To further explore the dynamics of the BCAS1+ oligodendrocytes in
the somatosensory cortex, we deleted the establishment of sister chro-
matid cohesion N-acetyltransferase 2 (Esco2) in the oligodendrocyte
lineage using the inducible Sox10-CreERT2 × Escofl/fl mouse line (re-
ferred to as Sox10-Escofl and Sox10-Esco2wt mice for control) to spe-
cifically ablate proliferating oligodendrocyte progenitor cells (30, 31).
Upon tamoxifen administration, Esco2 is depleted, resulting in a detri-
mental block of the cohesion apparatus and subsequent apoptosis of all
cells undergoing mitosis, that is, proliferating oligodendrocyte progen-
itor cells. To label the recombined cells, we crossed these mice with the
CAG-EGFP reporter mouse line to induce the permanent expression
of GFP. Recombination was induced by tamoxifen in adult mice (8 to
10 weeks of age), and the number of GFP+/BCAS1+ oligodendrocytes4 of 12
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 was quantified (Fig. 3, E toG). Although the number ofGFP+/BCAS1+
myelinating oligodendrocytes cells remained stable at 6 weeks after
induction (Fig. 3G), we found a marked reduction in the number of
GFP+/BCAS1+ premyelinating oligodendrocytes (reduction from 92.1 ±
3.1% in control to 29.5 ± 1.3% in the knockout; fig. S8C) and GFP+/
BCAS1+ myelinating oligodendrocytes (reduction from 97.6 ± 2.4%
in control to 13.9 ± 7.3% in the knockout) when animals were analyzed
16weeks after induction (Fig. 3, F andG).We therefore conclude that in
the cortex, BCAS1+ oligodendrocytes also represent a transient cell pop-
ulation being continuously generated from proliferating oligodendro-
cyte progenitor cells, albeit with a much longer lifetime as compared
to the corpus callosum.
Myelination continues into adulthood but declines
in aged mice
To determine the abundance of BCAS1+ cells in the white matter (cor-
pus callosum) and gray matter (somatosensory cortex), we compared
their density to NG2+ oligodendrocyte progenitor cells in young (P40)
and adult (4months) animals. BCAS1 staining of the corpus callosumof
adult, 4-month-old mice showed a marked reduction of labeled cells
compared to younger animals (P40) (fig. S9A). Quantification of the
number of BCAS1+ cells in the corpus callosum revealed numbers simi-
lar to NG2+ oligodendrocyte progenitor cells at P40 and at 4 months
(fig. S9A). Because of its transient expression, BCAS1 immunoreactivity
can serve as a tool to map areas with ongoing oligodendrocyte forma-
tion in the brain. Therefore, we determined the number of BCAS1+ oli-
godendrocytes up to old age (21-month-oldmice) in the somatosensory
and frontal cortex, areas that are known to myelinate relatively late.
BCAS1+ myelinating oligodendrocytes were found at a density of
715.5 ± 66.8 cells/mm3 in young (P40) mice and remained as an abun-Fard et al., Sci. Transl. Med. 9, eaam7816 (2017) 6 December 2017dant cell population in the adult mice (4 and 7 months of age), where
they were found in the somatosensory cortex at a density of 379 ±
11.9 cells/mm3 (4months) and347.7±26.6 cells/mm3 (7months; Fig. 4A)
and in the frontal cortex at a density of 206.4 ± 57.8 cells/mm3 (7months;
fig. S9B). Only in much older mice (21 months of age) that the number
of BCAS1+ myelinating oligodendrocytes decreased to low levels in the
somatosensory cortex (71.2 ± 11.7 cells/mm3; Fig. 4A). BCAS1+ pre-
myelinating oligodendrocytes were also found at higher densities in
the somatosensory cortex of young (P40) and adult (4 and 7 months)
mice compared to aged (21 months) mice (Fig. 4A). These results sug-
gested that generation of myelinating oligodendrocytes continues into
adulthood but declines in aged mice.
Using an alternative approach, we used amass spectrometrymethod
to determine the synthesis rate of myelin proteins from development
into old age. Thismethod is based on in vivo stable isotope labelingwith
amino acids inmice (SILAC) (32). Young (1 month), adult (4 months),
and old (18 and 26 months) mice were fed for 30 or 60 days with a diet
containing the stable 13C isotope incorporated in lysines (13C-lysines)
(Fig. 4B). Subsequently, myelin was purified from isolated brains by
density centrifugation, and the incorporation of 13C-lysines into pro-
teins was compared to the amount of native 12C-lysines by mass spec-
trometry to obtain a measure of their relative synthesis rates. The 13C-/
12C-lysine ratio of the three most abundant proteins of compacted
myelin— MBP, PLP, and claudin11—was compared to the ratio of the
three major structural proteins of axons—neurofilament light, medium,
and heavy chains—that copurify with myelin. Although the calculation
of the 13C/12C-lysine ratios revealed that the metabolism of neurofila-
ments had reached steady state in 4-month-old animals and remained
at similar level throughout the life, we found that this was not the case for
myelin proteins. The incorporation of the 13C-lysines into myelinFig. 3. BCAS1+ oligodendrocytes are a transient cell population. (A) Experimental design: 5-Ethynyl-2′-deoxyuridine (EdU) was administered to a 4-month-old mice
as shown in the scheme. Analyses were performed 10 (+0 days), 17 (+7 days), 28 (+18 days), and 50 (+40 days) days after injection. (B and C) Quantification of the
percentage of EdU+/BCAS1+ cells directly (0 days) and 40 days after the end of the treatment in the corpus callosum (B) and somatosensory cortex (C). Student’s two-
tailed t test, unpaired, *P < 0.05, ***P < 0.001. (D) Line graph showing the time-course expression analysis of the fraction of CC1+ oligodendrocytes that were EdU+ and
either BCAS1+ or BCAS1− plotted versus the time after the end of the EdU exposure in the corpus callosum. One-way ANOVA, followed by Newman-Keuls’ post hoc test,
*P < 0.05, **P < 0.01. (E) Experimental design: Proliferating OPCs were ablated by tamoxifen injection in inducible Sox10-iCreERT2 × Esco2fl/fl × CAG-EGFP mice (FL) and
compared to control animals Sox10-iCreERT2 × Esco2wt/wt × CAG-EGFP (WT). Esco2, establishment of sister chromatid cohesion N-acetyltransferase 2. Tamoxifen was
injected in 8- to 10-week-old animals, and analyses were performed 6 and 16 weeks after injection. Recombined cells are marked by EGFP. (F and G) Representative
images of BCAS1 and GFP expression in the somatosensory cortex of WT and FL mice 16 weeks after tamoxifen injection (F) and quantification of the percentage of
BCAS1+ mOLGs that are positive for GFP at 6 and 16 weeks postinduction (wpi) in the somatosensory cortex (G). Scale bars, 15 mm. Student’s two-tailed t test, unpaired,
**P < 0.01, ***P < 0.001. 6 wpi/WT versus 16 wpi/KO, P = 0.0028; 6 wpi/KO versus 16wpi/KO, P = 0.0028; 16 wpi/WT versus 16 wpi/KO, P = 0.0004. KO, knockout. For all
quantifications, n = 3 (only n = 2 for the +6 wpi group), three sections per animal. Quantitative data are means ± SEM.5 of 12
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 proteins occurred at a higher rate in 1- and 4-month-old mice when
compared to 18- and 26-month-old animals (Fig. 4B). Overall, the
high ratios of 13C-/12C-lysines in myelin proteins are consistent with
prominentmyelination at 1month, still activemyelination in 4-month-old
mice but reduced myelin protein synthesis in aged mice. Thus, our
SILAC-based quantification provides further evidence that myelination
continues into adulthood but declines in aged mice.
One of the possible reasons for adult myelination could be the ex-
tensive turnover of myelinating oligodendrocytes in adult mice. Hence,
we used the PLP-CreERT2×R26R-tdTomato-mEGFP reportermice to
induce the expression of EGFP by tamoxifen at P30 in oligodendrocytes
and to track the fate of developmentally born oligodendrocytes. We
followed these animals for up to 12months of age and found an increase
in EGFP signal intensity with time in corpus callosum and somato-
sensory cortex (fig. S10, A to D). When we quantified the density of
GFP+ cells in the somatosensory cortex of tamoxifen-treated transgenic
animals, we found that the number of GFP+ oligodendrocytes labeled
18 days after tamoxifen injection did not change over the 11 months of
chase, suggesting that developmentally born myelinating oligodendro-
cytes survive into late adulthood and expand their myelin sheaths
(fig. S10, E and F). Hence, these results do not support an extensive
turnover of myelinating oligodendrocytes but rather suggest that the
generation of new myelin sheaths in the adult is likely due to a matu-
ration or adaptive process that continues into adulthood in mice.Fard et al., Sci. Transl. Med. 9, eaam7816 (2017) 6 December 2017BCAS1+ oligodendrocytes are largely restricted to the fetal
and early postnatal human white matter but are numerous
in the gray matter until old age
Next, we set out to determinewhether the results obtained from rodents
also hold true for humans. Although a previouswork provided evidence
that the number of oligodendrocytes remains relatively stable through-
out human life (15), tools to visualize actively myelinating oligodendro-
cytes in human brain are lacking.When newborn human autopsy cases
(n = 3) were stained with BCAS1 antibodies, we observed, as in mice,
cells with multiple and branched processes (Fig. 5A). BCAS1+ cells co-
expressedOLIG2 and SOX10, suggesting oligodendroglial origin (Fig. 5,
A and B). On the contrary, only 3.5 ± 1.4% of the BCAS1+ cells was also
positive for NG2 (Fig. 5, A and B), and no cells were positive for the
proliferation marker Ki67 (fig. S11A). When we performed colabeling
withmarkers formature oligodendrocytes, tubulin polymerization pro-
moting protein (TPPP/p25), and CC1, only very limited (0.6 ± 0.3% for
TPPP/p25) or no overlap (0% for CC1), was seen (Fig. 5, A and B). We
also colabeled BCAS1 or NG2 with ENPP6. In human tissue, ENPP6
colocalized with NG2 (74.4 ± 5.3%), and the overlap with BCAS1 was
limited (12.2 ± 3.8%; fig. S11, B to F). We found that BCAS1+ cells dis-
played multiple, symmetrically radiating processes or segments aligned
in parallel closely resembling the morphology observed in mice. As in
mice, BCAS1+ cell bodies were not labeled with antibodies against PLP,
whereas some cellswere stainedwith antibodies againstMAG(9.8±2.4%Fig. 4. Myelination continues into adulthood but decreases in aged mice. (A) Cell density quantification (left) and immunohistochemistry (right) of BCAS1+ pre-
mOLGs and mOLGs in the somatosensory cortex in P40 and 4-, 7-, and 21-month-old mice. Scale bars, 30 mm. White and blue arrows indicate BCAS1+ pre-mOLGs and
BCAS1+ mOLGs, respectively. One-way ANOVA, followed by Newman-Keuls’ post hoc test, *P < 0.05, **P < 0.01. Student’s two-tailed t test, unpaired, for intergroup analysis,
*P < 0.05, ***P < 0.001. n = 3, three sections per animal. Quantitative data are means ± SEM. (B) Left (experimental design): Mass spectrometry analysis was performed in
1-, 4-, 18-, and 26-month-old mice fed for 30 or 60 days with a diet containing lysine labeled with 13C (13C-isotope). Right: The 13C isotope incorporation rates (13C-lysines/
12C-lysines ratio) are shown for three axonal proteins—neurofilament light (NFL), neurofilament medium (NFM), and neurofilament heavy (NFH) chains—and for the threemajor
myelin proteins—PLP, myelin basic protein (MBP), and CLD11; four animals per group, 4-month-old groups versus 18- and 26-month-old groups, one-way ANOVA, followed by
Bonferroni’s post hoc test. 30 days feeding: P < 0.0001, PLP; P = 0.0226, MBP; P < 0.0001, CLD11; P = 0.0800, NFH; P = 0.2355, NFM; P = 0.2700, NFL. 60 days feeding: P <
0.0001, PLP; P = 0.0016, MBP; P < 0.0001, CLD11; P = 0.1338, NFH; P = 0.0671, NFM; NFL, P = 0.0229. n = 4, three technical replicates. Error bars indicate SD.6 of 12
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 of overlap) andMBP (7.5 ± 1.4% of overlap) (fig. S11, G to I). Hence, we
found BCAS1+ oligodendrocytes to be distinct from NG2+oligodendro-
cyte progenitor cells, PLP+ premyelinating oligodendrocytes, andmature
oligodendrocytes.We therefore concluded thatBCAS1 immunoreactivity
identifies a unique stage of oligodendrocyte differentiation in the human
brain.Wemapped the distribution and the density of BCAS1+ cells in the
gray and white matter throughout life in human brains (Fig. 5, C to G,
fig. S12, and table S1). BCAS1+ cells started to appear in thewhitematter
at a gestational age of 17 to 27 weeks (37 ± 1.7 cells/mm2) and reached
their highest values in newborns (154.7 ± 20.8 cells/mm2) before drop-
ping to 16.8 ± 4.5 cells/mm2 in 2- to 8-year-old children. Their density
reached 6.8 ± 2.3 cells/mm2 in 18- to 26-year-old individuals and re-
mained low until old age (83 to 90 years old) (Fig. 5C). At 1 year of
age, abundant BCAS1+ myelin sheaths were observed in the white
and gray matter (Fig. 5D and fig. S12), further suggesting that BCAS1+
cells are likely to representmyelinating oligodendrocytes. In addition, the
number of BCAS1+ cells correlated with the established typical chrono-
logical sequence ofmyelination in the whitematter, suggesting that these
cells might be useful for identifying activemyelination. As a comparison,Fard et al., Sci. Transl. Med. 9, eaam7816 (2017) 6 December 2017we quantified the amount of NG2+ oligodendrocyte progenitor cells in
thewhitematter and found that the number of NG2+ cells also peaked in
newborns (260 ± 57.3 cells/mm2), but in contrast to BCAS1+ cells, the
density of NG2+ oligodendrocyte progenitor cells remained stable (166 ±
24 cells/mm2) throughout life into old age (Fig. 5C and fig. S12). Our
results suggest that, in contrast toNG2+ oligodendrocyte progenitor cells,
BCAS1+ cells are a transient cell population preferentially expressed
during the active phase of myelination in the human white matter.
Brain regions controlling more complex tasks, such as the frontal
cortex, generate myelin relatively late. We therefore determined the
number of BCAS1+ oligodendrocytes in the human frontal cortex and
found the highest densities during developmentalmyelination in adoles-
cence and young adulthood (Fig. 5, E and F). However, in contrast to the
white matter, the cell density did not change substantially, ranging from
30 to 90 cells/mm2 throughout adult life (Fig. 5, E and F). We deter-
mined the fraction of cells with a myelinating morphology (segments
aligned in parallel) and found the highest density in the 1- to 2-year-old
individuals (36.7 ± 4.3% of all BCAS1+ cells), followed by the 6- to
16-year-old individuals (17.3±4.9%), and2 to 4% in the 38- to 40-year-oldFig. 5. BCAS1+ cells represent a transient oligodendroglial subpopulation enriched during active myelination in the human brain. (A) Immunohistochemistry
showing colocalization of BCAS1 with OLIG2, NG2, CC1, and tubulin polymerization promoting protein (TPPP/p25). (B) Quantification of the percentage of BCAS1+ cells
positive for SOX10, OLIG2, NG2, TPPP/p25, and CC1 in newborns (n = 3 to 4). (C) Quantification of the density of BCAS1+ and NG2+ cells in the white matter throughout
development and adult life (BCAS1: 17 to 27 weeks, n = 2; all other time points, n = 3 to 5; NG2, n = 2 to 5 per time point; Mann-Whitney test,*P < 0.05, **P < 0.01; BCAS1
0 year versus BCAS1 2 to 8 years, P = 0.0357; BCAS1 2 to 8 years versus NG2 2 to 8 years, P = 0.0079; BCAS1 11 to 16 years versus NG2 11 to 16 years, P = 0.0159; BCAS1
18 to 26 years versus NG2 18 to 26 years, P = 0.0179; BCAS1 38 to 46 years versus NG2 38 to 46 years, P = 0.0357; BCAS1 83 to 90 years versus NG2 83 to 90 years, P =
0.0286). (D) BCAS1 expression in the white matter around birth (0 year) and at 1 year of age (1 year). Inset and image in the center show magnification of the BCAS1+
cells in a newborn human, as indicated by the arrowhead. (E) Quantification of BCAS1+ cell density in the frontal cortex (n = 3 to 6). (F) Representative images of BCAS1
expression in the frontal cortex in humans around birth (0 year) and at 2 to 8, 38 to 46, and 57 to 65 years of age (as indicated). The insets show magnifications of BCAS1+ cells,
as indicated by arrowheads, with few or no segments (left) and with several segments (right). (G) Percentage of BCAS1+ cells with a myelinating morphology in the frontal
cortex in humans at different ages; n = 3 to 5. Kruskal-Wallis test with Dunn’s post hoc test, *P < 0.05. Quantitative data are means ± SEM. Scale bars, 50 mm.7 of 12








 and 57- to 60-year-old individuals (Fig. 5G). These results contrast
with thewhitematter tracts and point to the possibility of adult adapt-
ive myelination in the human frontal cortex.
BCAS1+ oligodendrocytes are reformed in a proportion of
chronic white matter lesions in MS
Having shown that BCAS1+ oligodendrocytes are enriched in the fetal
and early postnatal white matter, we asked whether they are reformed
after a demyelinating event. We first used a mouse model of focal de-
myelination in the white matter induced by lysolecithin (lysophospha-
tidylcholine) injection. In lesioned animals, demyelination is complete
within 4 days, followed by a repair process that is maximal between 2
and 3 weeks after injection. We found that BCAS1+ cell density in-
creased from days 3 to 12 after injection in the phase of most intense
remyelination (Fig. 6, A and B). We repeated the analysis in a chronic
model of demyelination, in which mice are fed with a demyelinating
toxin, cuprizone, for 6 weeks. We observed that BCAS1+ cells de-
creased in the first week of feeding but already started to increase at
week 3 and reached their highest densities at week 4, coinciding with
remyelination (Fig. 6, C and D).
Next, we askedwhether BCAS1+ oligodendrocytes are also reformed
in human MS lesions. In MS, damaged myelin can be replaced by new
sheaths, but the ability to do so is limited (8). Thus far, weaker myelin
staining, so-called shadow plaques, is taken as evidence for remyelina-
tion, but this analysis does not provide information on the time point of
remyelination (33, 34).We found that completely demyelinated chronic
lesions in the white matter only rarely contained BCAS1+ oligodendro-
cytes (Fig. 7A and fig. S13A), consistent with the notion that remyelina-
tion is incomplete inMS (16). In contrast, partially remyelinated lesions,
as shown by the pale myelin staining at the borders of the lesions, con-
tained clusters of BCAS1+ oligodendrocytes (Fig. 7, A to E). The densityFard et al., Sci. Transl. Med. 9, eaam7816 (2017) 6 December 2017of the BCAS1+ oligodendrocytes was highest at the lesion border and
within the remyelinating areas but low in the lesion core, suggesting that
remyelination starts at the lesion border in the whitematter (Fig. 7, A
to H). BCAS1+ oligodendrocytes were also increased in the normal-
appearing white matter surrounding chronic lesions with remyelina-
tion (fig. S13). Our analysis ofMS lesions frompatients up to 74 years of
age showed that the capacity to generate ormaintain BCAS1+ oligoden-
drocytes is retained until old age (table S2). Finally, we examined lesions
that were fully remyelinated (completely covered with pale myelin cor-
responding to shadow plaques) and found that such lesions contained
low densities of BCAS1+ oligodendrocytes (Fig. 7, A to I, and fig. S13).
Thus, BCAS1+ oligodendrocytes are found in the predicted chron-
ological sequence of remyelination in human MS lesions, suggesting
that a proportion of these cells are engaged in actively reformingmyelin.
Finally, we determined whether inflammatory activity was a prerequi-
site for the presence of BCAS1+ oligodendrocytes in chronicMS lesions.
MS lesions were classified on the basis of the presence or absence of
macrophages/activated microglia (inflammatory activity) and the presence
or absence of ongoing demyelination (demyelinating activity) (Fig. 8, A
and B). We found that BCAS1+ oligodendrocytes were not only found
in lesions with ongoing inflammatory and/or demyelinating activity but
also in completely inactive lesions (Fig. 8, C and D), suggesting that re-
cruitment of oligodendrocyte progenitor cells and stimulation of remye-
lination are at least in part independent of lesion activity.by guest on Decem
ber 21, 2017DISCUSSION
The systematic classification of all neural cell types is a central goal
toward deconstructing the CNS into its basic components. Del Rio
Hortega grouped oligodendrocytes into different subtypes on the
basis of their morphological characteristics such as the number and ori-
entation of their cellular processes. Recent single RNA sequencing tran-
scriptome analyses confirm oligodendrocyte heterogeneity (35, 36).
Nonetheless, molecular tools to distinguish the cellular subtypes or
stages of the oligodendrocyte lineage are lacking. Currently, we are
largely restricted to the discrimination of oligodendrocyte progenitor
cells from mature oligodendrocytes in the human brain (37–39).
ENPP6 has recently been used as a marker to track the formation of
newly formed oligodendrocytes inmice (9); however, itmay not be suit-
able for this purpose in human tissue sections, as demonstrated in the
present work. PLP+ premyelinating oligodendrocytes were detected in
the developing and diseased human brain, but they seem to represent a
minor cell population of newly formed oligodendrocytes (24, 25). In
addition, most markers, such as O1 or O4, do not detect newly formed
oligodendrocytes in the adult and are more appropriate to the analysis
of the developing brain (40). Thus, to measure myelination and remye-
lination in human adults, we have thus far been limited to indirect
methods, such as magnetic resonance imaging in vivo and electron mi-
croscopy or semiquantitative histochemical staining techniques in the
tissue. In addition, as of yet, no marker for actively ongoing remyelina-
tion exists, and consequently, it has thus far not been possible to deter-
mine when new myelin sheaths are reformed in MS (33). Here, we
identified BCAS1+ oligodendrocytes in the mouse and human brain
that represent a population of newly generated and early oligodendro-
cytes transiently present during the active phase of myelination and
might thus be used to report areas of activemyelination and remyelina-
tion. BCAS1 is a relatively short-lived proteinwith a lifetime of ~18 days
[~155 days for MBP and ~188 days for PLP (calculations from our in
vivo SILAC experiments); see Materials and Methods] that resides inFig. 6. BCAS1+ oligodendrocytes are reformed during remyelination in ro-
dents. (A) Representative images of BCAS1 expression of lysolecithin-induced le-
sions in the rat corpus callosum on days 3 and 6 after injection. BCAS1+ cells are
shown in brown, and cell nuclei are shown in blue. (B) Quantification of BCAS1+
cell density in lysolecithin-induced lesions 3, 6, 12, and 20 days after injection (n = 3;
Kruskal-Wallis test with Dunn’s post hoc test, *P < 0.05). (C) Representative images of
BCAS1 expression in the corpus callosum 1 and 4 weeks after the start of cuprizone
treatment in mice. BCAS1+ cells are shown in brown, and cell nuclei are shown in
blue. (D) Quantification of BCAS1+ cell density in the corpus callosum 1 week after
the start of cuprizone treatment and 2 days remyelination (2d RM) and 3 weeks re-
myelination (3wks RM) after the treatment was discontinued; n = 4 to 14 animals.
Kruskal-Wallis test with Dunn’s post hoc test, *P < 0.05, **P < 0.01. Quantitative data
are means ± SEM. Scale bars, 50 mm.8 of 12
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 the cytosolic spaces of oligodendrocytes and myelin and is down-
regulated with differentiation. BCAS1 immunoreactivity is first seen
in the soma but later appears in newly formed myelin sheaths, sug-
gesting that BCAS1+ cells might represent myelinating oligodendro-
cytes.Whereas a fraction of the BCAS1+ cells represent oligodendrocyte
progenitor cells inmice, as determined byNG2colabeling, the overlap isFard et al., Sci. Transl. Med. 9, eaam7816 (2017) 6 December 2017less than 5% in humans. In addition,
BCAS1+ oligodendrocytes are also distinct
from TPPP/p25+ and CC1+ mature hu-
man oligodendrocytes but overlap fully
with SOX10 and OLIG2, demonstrating
that BCAS1+ cells are segregated fromother
known oligodendroglial subpopulations.
Inmice but not in humans, a large fraction
of the BCAS1+ cells colocalized with CC1;
this difference is possibly attributed to dif-
ferences in the expression pattern of CC1
in mice and human. Quantifying the den-
sity of BCAS1+ cells, we found a peak in
the first year of postnatal white matter de-
velopment, although they continued to be
present in relatively large quantities in the
frontal human cortex into old age. These
data are in good agreement with the birth
dating of oligodendrocytes by 14C inte-
gration, which showed that the number
of oligodendrocytes in the white matter
is largely established during the first years,
whereas gray matter oligodendrocytes
continue to be generated in adulthood
(15). The number of BCAS1+ cells also de-
clines in the white matter of adult mice,
but in contrast to humans, they were pres-
ent in relatively high density into adult-
hood before dropping to very low levels
in old age. Differences between mouse
and human oligodendrocytes are likely
to exist; however, currently, there are no
tools available to determine whether mye-
linating oligodendrocytes are formed
from oligodendrocyte progenitor cells or
preexisting immature oligodendrocytes
in humans. Thus, we cannot exclude the
interesting possibility that BCAS1+ gray
matter oligodendrocytes are long-lived
and represent a precursor cell population
for (re)myelination in the human brain.
In the prototypic human inflammatory
demyelinating disease MS, remyelination
is considered the prime neuroprotective
treatment strategy (8). Our work suggests
that active remyelination at the lesion edge
is ongoing in a proportion of established,
fully demyelinated MS lesions, even at ad-
vanced stages of the disease. Thus, older
patients are likely to remain receptive to
regenerative therapies,which is in linewith
the conclusions drawn from experimental
mousemodels (41). Surprisingly,we foundthat BCAS1+ oligodendrocytes were not only found in lesions with
ongoing inflammatory and/or demyelinating activity but also in com-
pletely inactive lesions.
There are anumberof limitations to thepresent study.Oligodendroglial
morphology, metabolism, and function are more complex and less well
understood in humans as compared to rodents (42). In addition, theFig. 7. BCAS1+ oligodendrocytes identify areas of ongoing remyelination in chronic multiple sclerosis. (A) Quan-
tification of BCAS1+ cell density in the normal-appearing white matter (NAWM), the immediate periplaque white matter
(PPWM), the lesion center (LC), and remyelinated lesion areas (RM), if present, of chronic demyelinated lesions (n = 10),
chronic lesions with areas of remyelination at the lesion edge (n = 18; ***P < 0.001), and fully remyelinated shadow
plaques (n = 7). Kruskal-Wallis test with Dunn’s post hoc test was used for statistical analysis. (B) Luxol fast blue/periodic
acid–Schiff (LFB/PAS) histochemistry depicts the frontal subcortical white matter containing a chronic demyelinated
multiple sclerosis lesion with two adjoining sharply delineated lesion areas of pale LFB staining (RM1 and RM2) and
a neighboring lesion area with more intense but still visibly reduced LFB staining [shadow plaque (SP)]. (C) BCAS1
immunohistochemistry on a serial section of (B). Frames in (C) and (D) indicate lesion areas depicted at a higher mag-
nification below. LB, lesion border. (D to J) Multiple sclerosis lesion areas as indicated in (C) immunostained for BCAS1.
Arrowheads indicate BCAS1+ cells. Error bars indicate SEM. Scale bars, 2 mm (B and C) and 50 mm (all other images).9 of 12
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 process of remyelination may operate on a different time scale and re-
quire additional cues in the human brain compared to the mouse brain
(43). Thus, even if we unraveled the dynamic nature of BCAS1+ oligo-Fard et al., Sci. Transl. Med. 9, eaam7816 (2017) 6 December 2017dendrocytes by lineage tracing in mice,
we cannot extrapolate these findings to
humans.As a consequence,wedonotknow
how long BCAS1+ oligodendrocytes persist
in thehumanbrain.We found thatBCAS1+
oligodendrocytes are formed in the fetal and
newborn brain, largely disappear from the
adult white matter, and are reformed in
MS lesions. Yet, we lack information on
their lifetime andcellular state inMS lesions.
Whether BCAS1+ oligodendrocytes in
humans represent newly formed or old
cells locked in an intermediate state of dif-
ferentiation cannot be determined to date.
Nevertheless, the observation that BCAS1+
cells are associated with partially remyeli-
nated lesions suggests that at least some of
these cells are actively engaged in forming
myelin.We envision that the identification
of BCAS1+ cells as an actively myelinating
oligodendroglial cell population inhumans
that segregates from oligodendrocyte pro-
genitor cells and mature oligodendrocytes
will have profound implications for the
functional analysis of myelination and




ological basis for efforts to identifymyelin-
regenerative compounds (44, 45).MATERIAL AND METHODS
Study design
The primary objective of this study was
to develop molecular tools to distin-
guish the cellular subtypes or stages of
the oligodendrocyte lineage. Immuno-
histochemistry and functional studies
including lineage tracing and cell and pro-
tein turnover studies were performed in
mice to establish BCAS1+ cells as an oli-
godendroglial subpopulation. The forma-
tion of BCAS1+ oligodendrocytes during
remyelination was determined in two ex-
perimental models of demyelination and
lysolecithin- and cuprizone-induced de-
myelination. Immunohistochemical studies
were performed to associate BCAS1+ cells
with developmental myelination along
the life span of a human brain. The brain
tissue of patients with MS was examined
to establish BCAS1+ cells as a cellular
marker of ongoing remyelination in the
disease. The number of biological repli-cates (n) per experiment is noted in each figure legend. The quan-
titative analyses were performed blinded. No outlier removal was
performed.Fig. 8. Ongoing remyelination occurs independently from multiple sclerosis lesion activity. (A) Representative
images showing the expression of the pan-macrophage/activated microglia marker KiM1P (brown) and MBP (blue) at
the rim of multiple sclerosis lesions. Rows represent different inflammatory and demyelinating lesion activities according
to Kuhlmann et al. (33). Insets in (A) highlight KiM1P+ phagocytes containing MBP+ particles. (B) Representative images
showing BCAS1 expression at the rim of multiple sclerosis lesions of varying inflammatory and demyelinating activity;
BCAS1+ oligodendrocytes are indicated by arrowheads. BCAS1+ oligodendrocytes extending multiple processes are
observed at the lesion rim in all stages of lesion activity. (C) Percentage of lesions with different inflammatory and
demyelinating activities containing areas of ongoing remyelination (ongoing RM) with BCAS1+ cells (n = 15). (D) Quan-
tification of BCAS1+ cell density in areas with ongoing remyelination of multiple sclerosis lesions of different
lesion activities (n = 15). Quantitative data are means ± SEM. Scale bars, 500 mm (A, left column) and 50 mm (all
other images).10 of 12
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All statistics were calculated using the GraphPad Prism 6 software
(GraphPad Software). The Kolmogorov-Smirnov test with Dallal-
Wilkinson-Lillie for P value was carried out to test for normal dis-
tribution. To compare the two groups, a Student’s two-tailed t test
or the Mann-Whitney test was applied. One-way analysis of variance
(ANOVA) followed by Bonferroni’s, Tukey’s, or Newman-Keuls’ post
hoc test was performed for comparison of three and more than three
groups, or one-way ANOVA with Kruskal-Wallis test with Dunn’s
multiple comparison tests was used as indicated in the figure legends.
Data are means ± SEM if not stated otherwise. Asterisks correspond to










Fig. S1. Validation of antiserum raised against BCAS1.
Fig. S2. BCAS1 specifically labels cells of oligodendrocyte lineage.
Fig. S3. Characterization of BCAS1+ pre-mOLGs and mOLGs.
Fig. S4. Characterization of ENPP6+ oligodendrocytes in mice.
Fig. S5. BCAS1 is down-regulated in fully matured oligodendrocytes prepared from mice.
Fig. S6. Comparison of BCAS1 with O1 and O4 immunolabeling.
Fig. S7. BCAS1 is down-regulated in fully matured oligodendrocytes prepared from human
iPSCs.
Fig. S8. Dynamics of BCAS1+ cells generation in adult mouse cortex.
Fig. S9. Quantification of the number of BCAS1+ cells in the adult mouse brain.
Fig. S10. Developmentally born mOLGs continue myelination into late adulthood.
Fig. S11. BCAS1+ oligodendrocytes are distinct from PLP+ and ENPP6+ oligodendrocytes in the
human brain.
Fig. S12. Characterization of BCAS1+ oligodendrocytes in the human brain.
Fig. S13. BCAS1+ oligodendroglia are rare in and around chronic demyelinated MS lesions and
fully remyelinated shadow plaques.
Table S1. Clinical characteristics of patients to study the developmental expression of BCAS1.
Table S2. Clinical characteristics of MS patients.
Table S3. Primary data.
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responses to remyelinating compounds for treating demyelinating disorders.
lesions, suggesting that remyelination might occur during MS and that BCAS1 expression could be used to track 
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